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Maternal infection during pregnancy increases the risk for schizo-
phrenia in offspring. In rodent models, maternal immune activa-
tion (MIA) yields offspring with schizophrenia-like behaviors.
None of these behaviors are, however, specific to schizophrenia.
The presence of hallucinations is a key diagnostic symptom of
schizophrenia. In mice, this symptom can be defined as brain
activation in the absence of external stimuli, which can be mimicked
by administration of hallucinogens. We find that, compared
with controls, adult MIA offspring display an increased stereo-
typical behavioral response to the hallucinogen 2,5-dimethoxy-
4-iodoamphetamine (DOI), an agonist for serotonin receptor 2A
(5-HT2AR). This may be explained by increased levels of 5-HT2AR
and downstream signaling molecules in unstimulated MIA pre-
frontal cortex (PFC). Using manganese-enhanced magnetic reso-
nance imaging to identify neuronal activation elicited by DOI
administration, we find that, compared with controls, MIA off-
spring exhibit a greater manganese (Mn2+) accumulation in sev-
eral brain areas, including the PFC, thalamus, and striatum. The
parafascicular thalamic nucleus, which plays the role in the path-
ogenesis of hallucinations, is activated by DOI in MIA offspring
only. Additionally, compared with controls, MIA offspring demon-
strate higher DOI-induced expression of early growth response
protein 1, cyclooxygenase-2, and brain-derived neurotrophic fac-
tor in the PFC. Chronic treatment with the 5-HT2AR antagonist
ketanserin reduces DOI-induced head twitching in MIA offspring.
Thus, the MIA mouse model can be successfully used to investigate
activity induced by DOI in awake, behaving mice. Moreover,
manganese-enhanced magnetic resonance imaging is a useful, non-
invasive method for accurately measuring this type of activity.
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Although it is possible to assay traits in animal models that aresimilar to those found in human schizophrenia, these traits
are also found in animal models of other neurodevelopmental
disorders such as autism spectrum disorder (ASD) (1, 2).
According to the Diagnostic and Statistical Manual of Mental
Disorders, Fifth Edition, hallucinations represent one such hall-
mark characteristic of schizophrenia but not of ASD. In humans,
serotonin receptor 2A (5-HT2AR) agonists, such as lysergic acid
diethylamide (LSD), mescaline, psilocybin, and 2,5-dimethoxy-
4-iodoamphetamine (DOI), can trigger effects similar to the
positive symptoms of schizophrenia such as delusions and hal-
lucinations (3, 4). Moreover, use of drugs plays a precipitating
role in the development of earlier onset of psychosis among
schizophrenic patients (5). We are investigating 5-HT2AR acti-
vation in a mouse model of an environmental risk factor for
schizophrenia and autism, maternal immune activation (MIA).
Offspring of infected or immune-activated pregnant mice and
rats exhibit a number of features associated with schizophrenia
including deficits in sensorimotor gating, latent inhibition and
social interaction, increased dopamine turnover and respon-
siveness, enhanced sensitivity to amphetamine and MK-801, and
ventricular enlargement. Moreover, several of these behavioral
abnormalities are adult-onset and reversed by antipsychotic
medications (6–8).
To study DOI-induced activity in MIA offspring, we de-
veloped an approach using manganese-enhanced magnetic res-
onance imaging (MEMRI). By taking advantage of the fact that
Mn2+ enters excitable cells via voltage-gated calcium channels,
MEMRI has been used to study cocaine-induced neuronal ac-
tivity (9), brain plasticity in song birds (10), and sound-evoked
activity (11, 12). The approach in the first two studies has some
limitations, as it is invasive, whereas the latter study required
exposure to a prolonged, repetitive stimulus. We developed
a noninvasive method to map brain regions of DOI-induced
activity in awake, behaving mice. Our approach decouples iso-
fluorane anesthesia, which is necessary for image acquisition,
from DOI administration and behavioral and brain responses to
the drug. We then used this method to analyze DOI-induced
brain activity in MIA and control offspring.
We next confirmed MEMRI data using immediate early gene
(IEG) induction as a surrogate of neuronal activity and in-
vestigated the effects of MIA on the expression of 5-HT2AR and
its downstream signaling molecules. Our data demonstrate that
DOI-induced hallucination-like activity can be modeled in the
MIA mouse model and MEMRI can be successfully used to
measure this kind of activity.
Significance
Here, we model a positive symptom of schizophrenia, hallu-
cination-like activity, in a mouse model of an environmental
risk factor of schizophrenia, maternal immune activation
(MIA). MIA offspring display an enhanced susceptibility to the
hallucinogen 2,5-dimethoxy-4-iodoamphetamine (DOI) and
demonstrate elevated DOI-induced brain activity as mea-
sured by induction of immediate early genes and manganese-
enhanced MRI. High sensitivity to DOI in MIA offspring can be
explained by an increased level of serotonin receptor 2A
(5-HT2AR) that mediates the effect of DOI on the prefrontal
cortex. Chronic treatment with the 5-HT2AR antagonist
ketanserin reduces DOI-induction of head twitching in MIA
offspring. Our data demonstrate that DOI-induced halluci-
nation-like activity can be modeled in the MIA mouse model
and suggest 5-HT2AR as a potential therapeutic target for
schizophrenia.
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Results
Compared with Control Offspring, MIA Offspring Exhibit Increased
Stereotypical Behavioral Responses to DOI. Drug-induced head
twitches are characteristic of animals exposed to hallucinogens,
and these are positively correlated with drug-induced halluci-
nations in humans (13–15). DOI-induced head twitches are eli-
cited by activation of 5-HT2ARs in the prefrontal cortex (PFC)
(14, 16, 17). We find that DOI induces this behavior in MIA and
control mice in a dose-dependent manner [F(1, 28) = 75.6, P <
0.0001 and F(1, 33) = 116.4, P < 0.0001 for 1 and 2 mg/kg DOI,
respectively; post hoc tests, P < 0.001 for both 1 and 2 mg/kg
DOI for control and MIA offspring] (Fig. 1A). However, com-
pared with controls, MIA offspring display a significantly greater
response [for 1 mg/kg DOI, F(1, 28) = 3.884, P = 0.059; post hoc
test, P < 0.05; for 2 mg/kg DOI, F(1, 33) = 3.56, P = 0.068; post
hoc test, P < 0.01].
Single i.p. Injection of MnCl2 Has No Significant Effect on General
Mouse Health and DOI-Induced Behavior and Brain Activity. Func-
tional magnetic resonance imaging (fMRI) is one of the most
widely used noninvasive neuroimaging methods that measure
functional brain activity in rodents (18). Our attempt to assess
global neural responses to DOI using a typical fMRI protocol
(18) was not successful. Possible explanations include a robust
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Fig. 1. DOI induces dose-dependent stereotypic behavior that is blocked by ketanserin. Compared with controls, MIA offspring display more head twitching
(A) in response to DOI (n = 9–13 from three to four litters per group, *P < 0.05). (B) Chronic blockade of 5-HT2Rs was achieved by daily injections of ketanserin
(2 mg/kg) i.p. for a week. Two days after the last injection, animals were treated with DOI (1 mg/kg) or saline, and the behavioral responses recorded for
30 min (n = 6–7 from three litters in DOI-treated groups with or without ketanserin; n = 4–5 from three litters in saline-treated groups with or without
ketanserin, *P < 0.05). Data are presented as mean ± SEM.
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Fig. 2. Effect of intraperinoneal injection of MnCl2 on mouse general health and DOI-induced head twitching. (A) Mice treated with MnCl2 (40 mmole/kg
body weight) displayed a dramatic decrease in the body temperature during first the 10 h after injection [F(1, 48) = 159.9, *P < 0.0001]. The mean baseline
temperature for the mice before MnCl2 exposure was 37.6 ± 0.1 °C. (B) Mice injected with MnCl2 maintain their body weight 24 h after injection [t(4) = 0.922,
P = 0.419]. To determine change in body weight, initial body weight was subtracted from body weight 24 h after injection. (C) MnCl2 has no significant effect
on DOI-induced behavioral response. Mice obtained MnCl2 injection i.p. (40 mmole/kg body weight) 24 h before behavior testing. On the day of the test,
animals were injected with 2 mg/kg DOI or saline, and their behavior was monitored for 30 min. Injections of MnCl2 did not affect DOI-induced head twitching
[F(1, 8) = 0.533, P = 0.486]. Data represent means ± SEM; n = 3 mice per treatment group.
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cardiovascular effect of DOI (19) due to the presence of
5-HT2AR within the vasculature (20). Moreover, even under
isofluorane anesthesia, the drug-induced body jerks and head
twitches make imaging extremely difficult. Isofluorane anesthe-
sia also blocked DOI-induced IEG early growth response protein
1 (egr-1) response (Fig. S1).
Therefore, to track brain activity in awake, freely moving animals,
we used a modified MEMRI protocol that decouples isofluorane
anesthesia and DOI administration. Previously, MEMRI was
successfully applied to analyze cocaine-, sound-, and odor-in-
duced activities (9, 11, 12, 21), as well as brain plasticity in song
birds (10). Because Mn2+ can be neurotoxic (22, 23), we carried
out a pilot experiment on naive, 6-wk-old C57BL/6J mice to
establish a protocol and study the effects of Mn2+ on general
animal health and DOI-induced behavior. We found that Mn2+
(MnCl2, 40 mmole/kg body weight) decreases body temperature
during the first 10 h (Fig. 2A). By 12 h, the body temperature was
36.97 ± 0.19 °C. To stabilize the body temperature, we kept ani-
mals on a heating pad during this time. With this precaution, no
significant effects of Mn2+ on body weight, DOI-induced head
twitching, or egr-1 activation were found (Figs. 2 B and C and 3).
The animals also received an i.p. injection of saline (300 μL per
mouse) 3 and 6 h after MnCl2 injection to keep them hydrated.
MIA Offspring Display Greater DOI-Induced Brain Activation as
Detected by MEMRI. To track brain activity in awake, freely
moving animals, we used a modified MEMRI protocol, in
which neuronal activity is imaged retrospectively, after DOI-
induced Mn2+ accumulation within activated neurons of awake,
behaving mice (Fig. 4). For the analysis, we apply an MEMRI-
based statistical parametric mapping (SPM) method that was
successfully used to measure sound-induced activity in a quan-
titative and unbiased manner (9, 12). We compare DOI-induced
Mn2+ uptake in MIA versus control offspring performing a 2 × 2
factorial analysis with drug (DOI or saline) and MIA [poly(I:C)
or saline] treatments as the independent factors and the signal
intensity difference before and after drug administration as the
dependent factor. Significant Drug × Group interactions are
identified, and these are overlaid onto a study-specific mini-
mum deformation template (MDT) and presented as statistical
parametric F-value maps (Fig. 5 and Table S1). The green color
represents areas with the cumulative effect of DOI in MIA
and control mice (Fig. 5, Right). A DOI effect is observed
throughout the brain, predominately in somatosensory cortices
and regions associated with motor function, often with later-
alization to a specific hemisphere. The primary motor area
(layer 6a), secondary motor area (layers 2, 3, and 5), primary
somatosensory area for the upper and lower limb, and caudate
putamen all display increased Mn2+ accumulation, with distinct
lateralization in the left hemisphere. An increase is also ob-
served in the orbital area; layers 1, 2, and 3 of the infralimbic
area; the dorsal part of the anterior cingulate; and the dorsal
portion of the taenia tecta layer 1. Bilateral increases are ob-
served in the medial group of the dorsal thalamus. Then, direct
comparison of the increases due to DOI in the MIA and control
groups was performed for the voxels that demonstrate statisti-
cally significant interaction effects in 2 × 2 factorial analysis
(Fig. 6A and Table S2; Student t test, P < 0.05). Here, red
indicates that the DOI response is significantly greater in MIA
compared with the control offspring; with blue representing the
reverse (Fig. 6B). The difference between MIA and control
offspring in response to DOI is observed in most of the areas
described above. The parafascicular thalamic nucleus (PTN)
is found to be activated by DOI in MIA offspring only.
Compared with MIA offspring, the control mice exhibit in-
creased DOI responses in very few brain areas. At this level of
significance, no difference is found between the signal dif-
ference from 24 and 27 h in MIA and control offspring who
received saline instead of DOI.
MIA Offspring Display Greater DOI-Induced egr-1, COX-2, and BDNF
Activation in the PFC than Control Offspring. The PFC plays a key
role in the control of DOI-induced head twitch behavior. Micro-
injections of DOI in the PFC elicit this type of stereotyped response
in rodents (16). Moreover, restoration of 5-HT2AR in the PFC of
5-HT2AR knockout mice is sufficient to mediate DOI-induced
activation of egr-1 as well as behavioral responses (14). DOI also
stimulates local 5-HT release, particularly in the PFC (24). Because
MIA offspring display elevated sensitivity to DOI and increased
Mn2+ accumulation in PFC as measured by MEMRI, we analyzed
DOI-induced activation of egr-1 in this part of the brain. We find
that 1 mg/kg of DOI significantly increases egr-1 mRNA production
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Fig. 3. MnCl2 has no significant effect on DOI-induced activation of IEG
egr1. Sensory cortices sampled are frontal (A), somatosensory (B), and
auditory (C).
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Fig. 4. The MEMRI experimental timeline is illustrated. Animals first un-
derwent a 46-min baseline scan a week before the beginning of the ex-
periment. On the first day, MnCl2 (40 mmole/kg body weight) was delivered
i.p., and 24 h later, the animals were imaged to measure the basal level of
Mn2+ uptake in the brain. After recovery from anesthesia, the animals re-
ceived two injections of DOI (2 mg/kg) or saline 1 h apart and were imaged
again 1 h after the last DOI injection. All imaging scans were done under 2%
isoflurane anesthesia.
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in both groups [F(1, 37) = 34.4, P < 0.0001; post hoc test, P < 0.05
for control mice and P < 0.001 for MIA offspring], but MIA
offspring display higher DOI-induced egr-1 activation in the PFC
than controls. The post hoc test of differences in response to
DOI reveals a significantly elevated egr-1 level in MIA offspring
(MIA twofold increase versus control 1.5-fold increase, P < 0.05)
(Fig. 7A).
DOI alters cyclooxygenase-2 (COX-2) expression, the key
enzyme in the synthesis of prostaglandins, in the rat parietal
cortex via stimulation of the PLA2 pathway (25). We find that
although the drug significantly increases COX-2 mRNA in both
groups [F(1, 41) = 13.37, P < 0.001; post hoc test, P < 0.05 for
control mice and P < 0.01 for MIA offspring], MIA offspring
display a threefold increase in COX-2 induction in the PFC
compared with a 1.5-fold increase in controls [F(1, 41) = 6.068,
P < 0.05; post hoc test, P < 0.05] (Fig. 7B).
The level of the neurotrophin brain-derived neurotrophic
factor (BDNF) is altered in schizophrenia (26), and DOI regu-
lates its expression in the hippocampus and neocortex (27). We
find that DOI increases BDNF mRNA in both MIA and control
groups [F(1, 36) = 8.19, P < 0.01; post hoc test, P < 0.02 for
control mice and P = 0.17 for MIA offspring). However, MIA
offspring display significantly higher DOI-induced BDNF
mRNA expression in the PFC than controls [F(1, 36) = 8.63, P <
0.01; post hoc test, P < 0.05] (Fig. 7C).
MIA Offspring Have an Increased Level of 5-HT2AR and Its
Downstream Signaling Molecules in the PFC. Compared with con-
trols, antipsychotic-free human schizophrenic subjects display an
increased 5-HT2AR level in the PFC (28). Moreover, rodent
models of schizophrenia, including MIA and prenatal or post-
natal stress, yield offspring with elevated 5-HT2AR in the PFC,
as well as a greater sensitivity to DOI (29–31). We find that,
compared with controls, MIA offspring exhibit a 50% increase in
5-HT2AR mRNA levels in the PFC [t(26) = 2.738, P < 0.05] (Fig.
7D). Moreover, MIA offspring display elevated mRNA levels for
phospholipase C (PLC) β1 and regulator of G protein signaling
4 (RGS4), which are regulated by 5-HT2AR [t(23) = 3.301, P <
0.005 and t(22) = 2.64, P < 0.05 for PLC β1 and RGS4, respectively].
No difference between MIA and control offspring is seen for cy-
toplasmic phospholipase A2 (cPLA2) [t(19) = 0.1299, P = 0.898],
serotonin transporter (SERT) [t(20) = 0.085, P = 0.933], and integrin
β 3 (ITGB3) [t(20) = 0.417, P = 0.682]. Moreover, we find that
5-HT2AR and PLC β1, but not RGS4, exhibit trending increases
at the protein level, consistent with our findings of significantly in-
creased mRNA expression for each gene [5-HT2AR, 20% increase,
t(10) = 1.849, P = 0.09; PLC β1, 30% increase, t(10) = 2.87, P < 0.02;
RGS4, no increase, t(10) = 0.2683, P = 0.79] (Fig. S2).
Chronic Ketanserin Treatment Reduces DOI Induction of Head
Twitching in MIA Offspring. 5-HT2AR is a treatment target
for many psychiatric diseases, particularly major depression
and schizophrenia (32–34). Injection of the 5-HT2AR an-
tagonist ketanserin in the PFC specifically inhibits DOI-
induced head twitch behavior (16). Moreover, postnatal ex-
posure to stress increases 5-HT2R and elevates sensitivity to
DOI, and chronic ketanserin in adulthood prevents enhanced
anxiety (35) and restores some of the DOI-induced gene ex-
pression changes in the PFC (29). We find that ketanserin
treatment for a week reduces DOI-induced head twitching in
MIA offspring (Fig. 1B) [pairwise multiple comparison for
ketanserin/saline treatment, F(1, 34) = 8.787, P < 0.01; for
DOI/saline treatment, F(1, 34) = 266.250, P < 0.001; for MIA
treatment, F(1, 34) = 0.0180, P = 0.894; post hoc test for DOI-
induced head twitch response after ketanserin treatment, P <
0.001 for MIA versus controls]. In contrast, 5-HT2AR
blockade has no effect on DOI-induced head twitching in
control offspring (post hoc test, P = 0.71). The effect of
ketanserin treatment on DOI-induced head twitching is not
due to acute blockade of 5-HT2AR, as the drug is cleared
from the organism by the time of behavioral testing (36).
Compared with nontreated animals, the head twitch response
to DOI is significantly higher in animals that underwent daily
handling and injections of ketanserin or saline for a week (Fig.
2A). This can be explained by the fact that repeated stress can
increase 5HT-2AR levels in the PFC (37).
Because 5-HT2AR plays a crucial role in schizophrenia, we
also checked the levels of 5-HT, its endogenous ligand, in whole
blood and the PFC of MIA offspring. Although there may be
a slight decrease in 5-HT in blood (1.29 ± 0.67 and 1.84 ± 0.51
ng/mg protein for MIA and control offspring, respectively) and
PFC (3.52 ± 1.19 and 4.73 ± 0.27 ng/mg protein for MIA and
control offspring, respectively), these differences do not reach
Drug Group Drug x Group
F stasc
5.69 15.0
F = 5.69 corresponds to α < 0.01; 
P < 0.0001 and cluster size of 36 voxels.
RHLH
Fig. 5. Statistical parametric maps of DOI-induced MEMRI signal in MIA and
control mice. MEMRI images were analyzed via voxel-by-voxel statistical
comparisons. Multifactorial analysis (2 × 2) for Drug × Group interaction was
performed. Drug (DOI or vehicle; red), group (MIA or control mice; blue),
and Drug × Group interaction (green) F statistical maps are overlaid on
coronal sections from a study-specific MDT. Corrections for multiple com-
parison effects were calculated using Alphasim, and significance was
reached at P < 0.0001, with a minimum cluster size of 36 voxels corre-
sponding to α = 0.01; n = 6 per group. (Scale bar, 1 mm.) LH, left hemi-
sphere; RH, right hemisphere.
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statistical significance [t(10) = 0.665, P = 0.26 and t(10) = 0.631,
P = 0.27 for blood and brain samples, respectively].
Discussion
The principal findings of this study are as follows: (i) in addition
to deficient prepulse inhibition (PPI) of the startle response
(Fig. S3), MIA results in offspring with a schizophrenia-like be-
havioral trait, namely, an elevated sensitivity to the hallucino-
genic drug DOI; (ii) MIA offspring display greater DOI-induced
egr-1, COX-2, and BDNF expression in the PFC; (iii) MEMRI
reveals that DOI stimulates the frontal, primary motor, and so-
matosensory cortices as well as caudate putamen and thalamic
Increase due to DOI administraon
1.8
MIA > Control Control > MIA
1.8 5.05.0
A B
LH RH
Fig. 6. DOI induces greater MEMRI signal increase in MIA versus control offspring. Significant group-wide comparison of signal increase due to DOI ad-
ministration between MIA and control mice identifies areas of increase (red) and decrease (blue) of MEMRI signal between the groups. (A) Semitransparent
renderings of the study-specific MDT and SPM overlays are displayed in axial, sagittal, and coronal profiles. (B) Specific coronal slices from the study-specific
MDT display the SPM overlays, with significance reached at P < 0.05 [t(11) = 1.81; n = 6 per group]. Only voxels identified demonstrating significant interaction
effects between drug and group are included in this figure. (Scale bar, 1 mm.) LH, left hemisphere; RH, right hemisphere.
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Fig. 7. MIA offspring display enhanced molecular responses to DOI in the PFC. The DOI induction of egr-1 (A), COX-2 (B), and BDNF (C) activation is greater
than in MIA than control PFC (n = 9–14 from four litters per group, *P < 0.05). (D) Compared with controls, MIA offspring display higher expression of
5-HT2AR, PLC β1, and RGS4 mRNA in the PFC (n = 10–12 from four litters per group, *P < 0.05 and **P < 0.005). No differences between the experimental
groups are seen for cPLA2, SERT, and ITGB3. The level of expression of each molecule of interest is normalized to beta-actin. Results are compared with the
control group and expressed as fold-change ± SEM.
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nuclei; (iv) Mn2+ uptake is significantly higher in all of these
areas in MIA offspring compared with control offspring; (v) the
PTN is the area of the brain activated by DOI in MIA offspring
only; (vi) differences in DOI-induced Mn2+ accumulation and
IEG expression can be explained by the increased levels of 5-
HT2AR, PLC β1, and RGS4 in the PFC of MIA offspring; (vii)
alterations in 5-HT2ARs are not due to changes in the levels of
serotonin, SERT, or ITGB3; and (viii) chronic treatment with
the 5-HT2AR antagonist ketanserin reduces DOI induction of
head twitching in MIA offspring.
Multiple genetic and environmental factors can contribute to
the etiology of schizophrenia (38). We and others have pre-
viously reported that the MIA mouse model yields offspring with
schizophrenia-like behaviors (30, 39–43). Moreover, another
environmental factor that can contribute to the onset of
schizophrenia is hallucinogenic drug abuse (3). LSD, DOI, and
psilocybin can induce schizophrenia-like psychosis in healthy
human subjects (3, 4, 44–46), and in the case of psilocybin, the
effect can be blocked by ketanserin. Furthermore, these drugs
induce schizophrenia-like traits in animals such as a PPI deficit
(47, 48) and stereotypic head twitches (16, 17, 49). Here, we
combined these two factors, MIA and an acute injection of
hallucinogenic drug DOI, and found that MIA offspring display
stronger DOI-induced behavioral responses and greater brain
activity as measured both by IEG induction and MEMRI. Ele-
vated sensitivity to DOI and up-regulation of egr-1 in the PFC
was also reported previously for offspring born to influenza-
infected or poly(I:C)-injected pregnant mice (30, 31). In addi-
tion, these mice also display a decreased density of metabotropic
glutamate 2 receptors (mGluR2s) in the PFC. 5-HT2AR and
mGluR2 can be expressed as a receptor heterocomplex in the
mouse and human brain, which may represent a new target for
antipsychotic therapies (50).
To characterize neuronal activation elicited by DOI adminis-
tration, we used an MEMRI approach using awake, freely moving
animals. Compared with earlier published approaches, where
MEMRI was used to analyze the action of pharmacological agents
(9), the present method is noninvasive and allows study of Mn2+
incorporation under a variety of behavioral situations. We found
that DOI stimulates Mn2+ uptake in the frontal, primary motor,
and somatosensory cortices as well as the caudate putamen,
midbrain, and thalamus (Fig. 5, Right and Table S1). Signal en-
hancement in the motor and somatosensory cortices can be
explained by increased locomotion activity, rearing, and groom-
ing. Altogether, our MEMRI data, positron emission tomog-
raphy (PET), and fMRI experiments in healthy human subjects
with another 5HT-2AR agonist psilocybin (51, 52) identify the
PFC and thalamus as key brain regions mediating the effects of
hallucinogens. Moreover, compared with control offspring, MIA
offspring display significantly higher DOI-induced brain activity
in most of the described areas (Fig. 6 and Table S2). In-
terestingly, MIA offspring, but not the controls, display DOI-
induced Mn2+ accumulation in the PTN, one of the intralaminar
nuclei of the dorsal thalamus that is known to play a role in the
pathogenesis of the visual and auditory hallucinations (53, 54).
We focus our study on PFC, as it plays an important role in
cognition, mood, anxiety, and sensory gating. Clinical, neuro-
psychological, and neuroimaging studies demonstrate PFC dys-
function in schizophrenia (55–57). Because this area of the brain
receives dense serotonergic innervation, abnormalities of the
serotonergic pathway have been proposed to contribute to the
pathophysiology of schizophrenia (58, 59). 5-HTRs are highly
expressed in human and rodent PFC and regulate PFC excit-
ability (60–62). We focused on 5-HT2AR and its signaling
pathway, as this receptor is a direct target of DOI (17). Com-
pared with controls, MIA offspring display an elevated level of
5-HT2AR in the PFC, which can explain the deficit of sensory
gating and greater DOI-induced schizophrenia-like behavior and
brain activity in these animals. Increased 5-HT2AR in the PFC
was also reported for other rodent models that exhibit high
sensitivity to DOI (29–31). Moreover, similar observations were
made in antipsychotic-free schizophrenic subjects (28). Increased
5-HT2AR in MIA offspring may be explained by a higher density
of pyramidal neurons that express this receptor, which was shown
previously for the maternal influenza mouse model (63). An-
other possible cause for 5-HT2AR elevation in MIA offspring is
that MIA may lead to activation of DNA methyltransferase 1
(DNMT1), which hypermethylates the 5-HT2AR promoter and,
as a result, increases 5-HT2AR expression. There is a positive
correlation between DNMT1 expression and the level of allele
C-specific methylation of the 5-HT2AR promoter in the tem-
poral cortex of schizophrenia patients, and this can significantly
affect expression of the receptor (64).
5-HT2AR is a Gαq protein-coupled receptor, and it activates
multiple signaling pathways including the PLC β1 and PLA2
cascades and activation of Ca2+ channels (65, 66). Moreover,
deletion of the Gq gene results in the lack of DOI-induced head
twitches (67). The complexity of 5-HT2AR signaling may help to
explain the paradox of why structurally similar 5-HT2AR ligands
differ in their hallucinogenic effects. We find that DOI activation
of 5-HT2AR results in an increased expression of egr-1, COX-2,
and BDNF mRNAs. Compared with controls, MIA offspring
demonstrate higher levels of all three targets.
Egr-1 is an IEG whose expression can be activated by PLC β1.
Thus, the higher induction of egr-1 expression by DOI in MIA
offspring compared with controls may be due to the elevated
PLC β1 level in the MIA offspring. Contradictory findings on
PLC β1 expression in the PFC of schizophrenia patients have
been reported (68, 69). This discrepancy may be due to differ-
ences in the state of the disease or therapy in these patient
cohorts. Interestingly, a recent study reported an elevated rate of
PLC β1 gene deletions in schizophrenia patients (70). In addi-
tion, compared with controls, MIA offspring display an elevated
RGS4 level in the PFC. RGS4 is a modulator of G protein and
Ca2+ signaling and is highly expressed in the PFC. RGS4 sup-
presses Gα subunit activity by promoting hydrolysis of GTP and
by antagonizing the regulation of Gα effectors (71). The elevated
levels of RGS4 in the PFC of MIA offspring may represent an
adaptive mechanism to reduce 5-HT2AR–mediated Gαq over-
activity, which causes activation of PLC β1 and Ca2+ signaling
pathways. Although there are decreased levels of RGS4 in
schizophrenia patients (72), RGS4 knockout mice do not display
relevant behavioral abnormalities (73).
Expression of COX-2 and BDNF is very rapidly induced by
neuronal activity (74, 75). Moreover, DOI increases expression
of these genes in the rat parietal cortex (25, 27). We confirmed
this in the mouse PFC. MIA offspring display not only higher
basal COX-2 and BDNF expression than controls but also an
increased response to DOI. Increased COX-2 and BDNF levels
are also found in schizophrenia patients (76, 77).
Because MIA offspring display increased 5-HT2AR levels, we
also checked other components of the serotonergic system such
as 5-HT, as well as SERT and ITGB3, which are involved in
5-HT transport. We found that MIA has no effect on basal 5-HT
content in the PFC. Similar findings were reported for the MIA
mouse model earlier (39, 78). Moreover, MIA does not change
basal expression of SERT and ITGB3. Therefore, alterations in
the 5-HT2ARs but not in the level of serotonin, SERT, or ITGB
in MIA offspring contribute to schizophrenia-related traits such
as high sensitivity to hallucinogenic drugs.
Although many atypical antipsychotic drugs typically used to
treat schizophrenia are relatively potent 5-HT2AR antagonists,
they also display properties of antagonists/inverse agonists at
other (particularly dopaminergic, histaminergic, and/or adren-
ergic) neurotransmitter receptors. Therefore, the search for
highly selective antagonists for 5-HT2AR is needed (79). To
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date, there are a few studies that show that 5-HT2AR antagonist
ketanserin inhibits psilocybin-induced acute hallucinatory states
and a psychosis-like syndrome in humans (4, 45, 46). Ketanserin
was also used previously to chronically block 5-HT2AR in a rat
model of psychiatric vulnerability that displays high sensitivity to
DOI and an increased level of 5-HT2AR in the PFC (29, 35).
Those animals displayed increased DOI-induced heat twitching
response and altered PFC transcriptome, components of which
overlap with gene expression changes seen with DOI stimulation.
We found that systemic treatment with ketanserin reduces DOI-
induced head twitching in MIA offspring. Although ketanserin
treatment has the effect on MIA offspring, it does not influence
a baseline response in the control group. A possible explanation
may be that MIA mice display elevated 5-HT2R function that is
mediating the response to DOI, and chronical blockade of
5-HT2AR predominantly modulates its expression in MIA mice.
In conclusion, here we model a positive symptom of schizo-
phrenia, hallucination-like activity, in a mouse model of an en-
vironmental risk factor of schizophrenia, MIA. MIA offspring
display an enhanced susceptibility to the psychomimetic actions
of DOI and demonstrate elevated DOI-induced brain activity
as measured by IEG induction and MEMRI. The increased
5-HT2AR expression and the ability of ketanserin to reduce
DOI-induced head twitching in MIA offspring suggest 5-HT2AR
as a potential therapeutic target for schizophrenia. Moreover,
understanding the mechanism of hallucinogen actions on the
brain may help identify new treatment options and should in-
crease the awareness of the dangers of abuse of such drugs.
Materials and Methods
Animals. Pregnant female C57BL/6J mice (Charles River) were obtained from
the California Institute of Technology breeding facility and were housed
under standard laboratory conditions. All animal protocols were approved by
the Institutional Animal Care and Use Committee of the California Institute
of Technology. On E10.5, pregnant females were weighed and randomly
assigned to poly(I:C) or saline groups. The offspring were weaned at 3 wk of
age, andmales were caged in groups of two to four. All behavioral tests were
conducted between 900 and 1700 h during the light phase of the circadian
cycle. Only male offspring were tested to avoid the effects of ovarian hor-
mones on female behavior.
Administration of Poly(I:C). One group of mice was given 5 mg/kg poly(I:C)
(potassium salt; Sigma) or saline i.p. on E10.5, 12.5, and 14.5, as was reported
previously (1). The manufacturer supplies poly(I:C) at 10% of the total
weight of the salt, and the dosage was based on the weight of poly(I:
C) itself.
DOI-Induced Stereotyped Behavior. Eight- to 10-wk old control and MIA
offspring received (±)DOI hydrochloride (1 or 2 mg/kg, i.p.) (Sigma) or saline.
Twenty-four hours before injection, the animals were single housed and
moved to a quiet testing room with red light to decrease the effects of
external stimuli on the sensory cortex. Behavioral responses to the drug or
vehicle were recorded in the home cage for 30 min after the injection. Head
twitches were defined as rapid radial movements of the head and were
counted by an experimenter blind to the treatment group.
Quantitative RT-PCR. Quantitative RT-PCR (qRT-PCR) was performed to de-
termine the influence of MIA on 5-HT2AR, PLC β1, cPLA2, RGS4, SERT, and
ITGB3 mRNA expression in unstimulated animals. In a separate experiment,
we analyzed how DOI stimulates mRNA expression of IEGs such as egr-1,
COX-2, and BDNF in the PFC of MIA and control offspring. IEG activation was
measured after 1 h of stimulation with DOI (1 mg/kg).
To collect brain samples, mice were anesthetized using Nembutal and then
decapitated. Brains were removed and washed in ice-cold, RNase-free saline
for 1–2 min. The PFC was dissected, homogenized in TRIzol (15 mg tissue per
600 μL), frozen in dry ice, and stored at −80 °C until processed for total RNA
isolation. Total RNA was extracted following the manufacturer’s protocol
(Qiagen), reverse-transcribed using an iScript cDNA Synthesis Kit (Bio-Rad),
and subjected to qPCR using FastStart SYBR Green Master (Roche Applied
Science) and the Applied Biosystems 7300 Real-Time PCR System (Applied
Biosystems). Quantification was determined using the Ct method as de-
scribed in the manufacturer’s protocol (Applied Biosystems). Data from all
groups were normalized to β-actin. Each sample was run in triplicate. Results
were compared with the control group and expressed as fold-change ± SEM.
The primers were chosen to span an intron to avoid the detection of any
contamination of genomic DNA. Table S3 lists the primers used.
Blockade of the 5-HT2AR. To block 5-HT2ARs, control and MIA animals were
treated with the 5-HT2AR antagonist ketanserin (Sigma) (2 mg/kg) or saline
i.p. daily for 7 d. The half-life of ketanserin in plasma is about 15 h (36). Two
days after the last injection, when the drug was totally cleared, the animals
were assessed for behavioral responses to DOI (1 mg/kg). This approach
allows analysis of effects of ketanserin on gene expression, in the ab-
sence of acute 5-HT2AR blockade.
Determination of 5-HT Content. Mouse blood was drawn by cardiac puncture
using citrate–dextrose solution (Sigma). Platelets were lysed by addition of
buffer [20 mM Tris·HCl, pH 7.8, 1.25 mM EDTA, 120 mM NaCl, 0.5% Nonidet
P-40, 0.5% Triton, Complete Protease Inhibitor Mixture, EDTA-free and
PhosSTOP-Phosphatase Inhibitor Mixture (Roche Applied Science)]. The 5-HT
content in mouse whole blood was measured using a 5-HT ELISA Kit (Eagle
Biosciences, Inc.). The amount of 5-HT was normalized to 1 mg of total
protein. The protein concentration was measured using CB-X Protein Assay
(G-Biosciences, A Geno Technology, Inc.).
Statistical Analysis. Statistical analysis for behavioral data and qRT-PCR was
performed using Prism 4.0b (Graphpad) and SigmaPlot 10 (Systat Software).
Experiments with two groups were analyzed using the unpaired Student t
test. Experiments with two variable factors were subjected to two-way
ANOVA, followed by a Bonferroni post hoc test. Experiments with three
variable factors were subjected to three-way ANOVA, followed by a Bon-
ferroni post hoc test.
MEMRI. Fig. 4 illustrates the timeline of the MEMRI protocol. Mice were im-
aged 1 wk before administration of Mn2+ to acquire a baseline image. On the
first day of the experiment all animals received MnCl2 (40 mmole/kg body
weight) i.p. After MnCl2 injection the animals were moved to a room with red
light. Twenty-four hours following MnCl2 injection, mice were imaged to
measure the basal level of Mn2+ uptake in the brain. After imaging, the
animals were returned to the room with red light. After 1 h of recovery from
anesthesia, the animals were injected i.p. with DOI (2 mg/kg) or saline twice,
1 h apart. Then, 1 h after the last injection, the animals were imaged again
to measure DOI-induced Mn2+ uptake in the brain.
An 11.7 T 89 mm vertical bore Bruker BioSpin Avance DRX500 scanner
(Bruker BioSpin) equippedwith aMicro 2.5 gradient systemwas used to acquire
all mouse brain images with a 35 mm linear birdcage radio frequency (RF) coil.
During imaging each animal was anesthetized with 2% (vol/vol) isoflurane,
and its head was secured in a Teflon stereotaxic unit within the RF coil to
minimize movement and to aid in reproducible placement. Temperature and
respiration were continuously monitored during data acquisition, with the
temperature controlled at 37 °C and respiration maintained at 100–120/min.
Similar to previous MEMRI studies (80, 81), we used a 3D rapid acquisition
with relaxation enhancement (RARE) imaging sequence (82) with a RARE
factor of 4 and the following parameters: 4 averages; repetition time/
effective echo time, 250 ms/12 ms; matrix size,160 × 128 × 88; field of view,
16 mm × 12.8 mm × 8.8 mm—yielding 100 μm isotropic voxels with a 46-min
scan time. MR images were skull-stripped using MIPAV (http://mipav.cit.nih.
gov/clickwrap.php). After skull-stripping, each image was scaled to the mode
of its intensity histogram. Inaccuracies were corrected by manual revision of
the masks in either image processing tool. The average time point images
from the 24 and 27 h time points were used to generate an MDT. All images
were warped to this MDT and then blurred with 0.3 mm Gaussian kernel
(Automatic Image Registration) (83). Signal intensity difference (SID) images
were generated by subtracting the 24 h time point image from the 27 h time
point image for each animal.
To identify DOI-induced brain responses in control and MIA offspring, we
applied SPM analysis, a voxel-based approach, which is generally used to
measure functional brain activity and identify regionally specific responses to
experimental factors (9, 12, 84). The images were assessed using a 2 × 2
ANOVA with the SID as the dependent variable and drug (DOI or vehicle)
and MIA treatment [poly(I:C) or saline] as the independent variables. The
voxels that demonstrate a statistically significant interaction between de-
pendent variables were identified. Corrections for multiple comparison
effects were calculated using Alphasim (http://afni.nimh.nih.gov/pub/
dist/doc/program_help/AlphaSim.html), and significance was considered
reached at P < 0.0001 with a minimum cluster size of 36 voxels corresponding
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to α = 0.01, n = 6 per group. Approximately 7% (39,670) of nonzero voxels
in the MDT were identified as statistically significant, which corresponds to
less than 2.3% of all voxels in the image field of view. DOI-induced activity
patterns were represented using statistical parametric maps of F values
derived from MEMRI images. Voxels that demonstrated a statistically sig-
nificant interaction between the dependent variables were then in-
vestigated to determine the origin of this interaction. The SID images for
the MIA and control groups were assessed to identify if the signal changes
due to drug administration were different. Student t test for independent
means in a group-wise manner was applied, and statistical significance was
reached at P < 0.05 [t(11) = 1.81, n = 6 per group]. Parametric maps of voxels
with statistically significant changes in intensity were created to display the
results and to correlate increases with underlying anatomy (Allen Brain
Atlas, http://mouse.brain-map.org/). The areas of parametric maps that did
not correspond to known anatomical regions were automatically excluded
from the data analysis. Although all MEMRI analyses presented were cor-
rected for multiple comparison effects, there were select brain regions
(hippocampus and cerebellum) with a strong MR signal contrast at their bor-
ders. It is difficult to determine if this is truly activation or an artifact of the
warping analysis approach. The signal in the white matter is the result of Mn2+
transport, as it is known that Mn2+ not only accumulates in active neurons, but
it is also transported along axons and it can be observed in several synapses
along a circuit (10, 85). Our manuscript focuses on prefrontal, motor, and sensory
cortices and thalamus as primary sites of DOI effect, and thus, the identified
border-rich regions of the hippocampus and cerebellum as well as white matter
are not target regions of interest. Additional experiments should be conducted
to validate whether identified sites exhibit direct activation or distal accumula-
tion or Mn2+ via axonal transport, but are out of the scope of this paper.
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